文章摘要
王玉琪,林蓓蓓,喻 芳,刘 静,唐 毅.宫颈脱落细胞SOX9基因甲基化与宫颈癌进展的关系及其联合血清SCCA、CA125的诊断价值研究[J].,2023,(3):505-509
宫颈脱落细胞SOX9基因甲基化与宫颈癌进展的关系及其联合血清SCCA、CA125的诊断价值研究
Relationship between the Methylation of Sox9 Gene in Cervical Exfoliated Cells and the Progression of Cervical Cancer and the Diagnostic Value Study of Combined Serum SCCA and CA125
投稿时间:2022-05-24  修订日期:2022-06-21
DOI:10.13241/j.cnki.pmb.2023.03.021
中文关键词: 宫颈癌  宫颈脱落细胞  性别决定基因9  鳞状细胞癌抗原  糖链抗原125  诊断价值
英文关键词: Cervical cancer  Cervical exfoliated cells  Sex determining gene 9  Squamous cell carcinoma antigen  Carbohydrate antigen 125  Diagnostic value
基金项目:湖南省卫生健康委科研计划项目(B20182012)
作者单位E-mail
王玉琪 湖南师范大学附属长沙市妇幼保健院妇一科 湖南 长沙 410000 whrbb322@163.com 
林蓓蓓 湖南师范大学附属长沙市妇幼保健院妇一科 湖南 长沙 410000  
喻 芳 湖南师范大学附属长沙市妇幼保健院妇一科 湖南 长沙 410000  
刘 静 湖南师范大学附属长沙市妇幼保健院妇一科 湖南 长沙 410000  
唐 毅 湖南师范大学附属长沙市妇幼保健院检验科 湖南 长沙 410000  
摘要点击次数: 579
全文下载次数: 350
中文摘要:
      摘要 目的:探讨宫颈脱落细胞性别决定基因9(SOX9)基因甲基化与宫颈癌进展的关系及其与血清鳞状细胞癌抗原(SCCA)及糖链抗原125(CA125)联合检测在宫颈癌中的诊断价值。方法:选取自2018年1月至2020年1月期间于湖南师范大学附属长沙市妇幼保健院治疗的64例宫颈癌患者(宫颈癌组)和50例宫颈上皮内瘤变(CIN)患者(CIN组),以同期40例健康体检者作为对照组。比较三组研究对象宫颈脱落细胞SOX9基因甲基化、血清SCCA、CA125水平。评估不同临床病理特征宫颈癌患者SOX9基因甲基化水平差异。采用Pearson相关性分析SOX9基因甲基化水平与血清SCCA、CA125之间的关系。采用受试者工作特征(ROC)曲线评估SOX9、SCCA、CA125单独及联合检测诊断宫颈癌的效能。结果:宫颈癌组在宫颈脱落细胞SOX9甲基化评分、血清SCCA、CA125水平均明显高于对照组及CIN组(P<0.05)。临床分期Ⅲ期、低分化及伴淋巴结转移的宫颈脱落细胞SOX9基因甲基化水平明显高于临床分期Ⅰ~Ⅱ期、高中分化及无淋巴结转移(P均<0.05)。宫颈癌组宫颈脱落细胞SOX9基因甲基化水平与血清SCCA、CA125呈正相关性(P<0.05)。宫颈脱落细胞SOX9基因甲基化水平及血清SCCA、CA125单独及联合检测的曲线下面积分别为0.793、0.718、0.650、0.841,联合检测对宫颈癌诊断的曲线下面积显著高于血清SOX9、SCCA、CA125单独检测(P<0.05)。结论:SOX9基因甲基化程度与宫颈癌恶性进展有关,宫颈癌组SOX9基因甲基化、SCCA、CA125水平明显升高,SOX9基因甲基化、SCCA、CA125联合检测对宫颈癌具有更高的诊断效能。
英文摘要:
      ABSTRACT Objective: To investigate the relationship between the methylation of sex determining gene 9 (Sox9) in cervical exfoliated cells and the progression of cervical cancer, and the diagnostic value of combined detection with serum squamous cell carcinoma antigen (SCCA) and carbohydrate antigen 125 (CA125) in cervical cancer. Methods: A total of 64 patients with cervical cancer (cervical cancer group) and 50 patients with cervical intraepithelial neoplasia (CIN group) who were treated in Changsha Maternal and Child Health Hospital Affiliated to Hunan Normal University from January 2018 to January 2020 were selected, and 40 healthy subjects in the same period were selected as the control group. The SOX9 gene methylation, serum SCCA and CA125 levels in cervical exfoliated cells of the three groups were compared. The differences of SOX9 gene methylation in cervical cancer patients with different clinicopathological features were evaluated. Pearson correlation was used to analyze the relationship between the SOX9 gene methylation and serum SCCA and CA125 levels. Receiver operating characteristic (ROC) curve was used to evaluate the efficacy of SOX9, SCCA and CA125 alone and in combination in the diagnosis of cervical cancer. Results: SOX9 gene methylation score, serum SCCA and CA125 levels in cervical cancer group were significantly higher than those in control group and CIN group (P<0.05). The SOX9 gene methylation level in cervical exfoliated cells with clinical stage Ⅲ, low differentiation and lymph node metastasis was significantly higher than that in clinical stage Ⅰ~Ⅱ, high and moderate differentiation and no lymph node metastasis (all P<0.05). The SOX9 gene methylation level in cervical exfoliated cells was positively correlated with serum SCCA and CA125 in cervical cancer group(P<0.05). The area under the curve of SOX9 gene methylation level in cervical exfoliated cells and the area under the curve of serum SCCA and CA125 were 0.793, 0.718, 0.650 and 0.841 respectively. The area under the curve of combined detection for cervical cancer diagnosis was significantly higher than that of serum SOX9, SCCA and CA125 alone(P<0.05). Conclusion: The degree of SOX9 gene methylation is related to the malignant progression of cervical cancer. The SOX9 gene methylation, SCCA and CA125 levels are significantly increased in the cervical cancer group, and the combined detection of SOX9 gene methylation, SCCA and CA125 has higher diagnostic efficacy for cervical cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭